Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer's Disease Neuroimaging Initiative.

Lancet Neurol. 2019 Nov;18(11):1034-1044. doi: 10.1016/S1474-4422(19)30283-2. Epub 2019 Sep 13.

PMID:
31526625
2.

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.

Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, Campos N, Jennett C, Sharma M, Simms KT, Smith MA, Velentzis LS, Brisson M, Jit M.

Papillomavirus Res. 2019 Sep 7;8:100184. doi: 10.1016/j.pvr.2019.100184. [Epub ahead of print]

3.

Added value of amyloid PET in individualized risk predictions for MCI patients.

van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, Berkhof J, van der Flier WM.

Alzheimers Dement (Amst). 2019 Jul 29;11:529-537. doi: 10.1016/j.dadm.2019.04.011. eCollection 2019 Dec.

4.

Who Will Benefit From Expanding HPV Vaccination Programs to Boys?

Qendri V, Bogaards JA, Berkhof J.

JNCI Cancer Spectr. 2018 Dec 21;2(4):pky076. doi: 10.1093/jncics/pky076. eCollection 2018 Oct.

5.

Role of FAM19A4/miR124-2 methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study.

Kremer WW, Berkhof J, Bleeker MC, Heideman DA, van Trommel NE, van Baal MW, Verhoeve HR, Meijer CJ, Kenter GG.

BMJ Open. 2019 Jul 9;9(7):e029017. doi: 10.1136/bmjopen-2019-029017.

6.

Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study.

Carlier A, Berkhof JG, Rozing M, Bouckaert F, Sienaert P, Eikelenboom P, Veerhuis R, Vandenbulcke M, Berkhof J, Stek ML, Rhebergen D, Dols A, Exel EV.

J Affect Disord. 2019 Sep 1;256:509-516. doi: 10.1016/j.jad.2019.06.040. Epub 2019 Jul 1.

PMID:
31279250
7.

Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.

Dick S, Kremer WW, De Strooper LMA, Lissenberg-Witte BI, Steenbergen RDM, Meijer CJLM, Berkhof J, Heideman DAM.

Gynecol Oncol. 2019 Aug;154(2):368-373. doi: 10.1016/j.ygyno.2019.06.002. Epub 2019 Jun 8.

PMID:
31182225
8.

Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands.

Polman NJ, de Haan Y, Veldhuijzen NJ, Heideman DAM, de Vet HCW, Meijer CJLM, Massuger LFAG, van Kemenade FJ, Berkhof J.

Prev Med. 2019 Aug;125:5-11. doi: 10.1016/j.ypmed.2019.04.025. Epub 2019 May 2.

PMID:
31054907
9.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

10.

Estimating the Human Papillomavirus Genotype Attribution in Screen-detected High-grade Cervical Lesions.

Lissenberg-Witte BI, Bogaards JA, Quint WGV, Berkhof J.

Epidemiology. 2019 Jul;30(4):590-596. doi: 10.1097/EDE.0000000000001026.

PMID:
30985528
11.

Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.

Neefjes ECW, van der Wijngaart H, van der Vorst MJDL, Ten Oever D, van der Vliet HJ, Beeker A, Rhodius CA, van den Berg HP, Berkhof J, Verheul HMW.

BMC Palliat Care. 2019 Mar 29;18(1):31. doi: 10.1186/s12904-019-0416-7.

12.

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies.

Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA; AMYPAD Consortium.

EJNMMI Res. 2019 Mar 27;9(1):32. doi: 10.1186/s13550-019-0499-4.

13.

Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer.

Neefjes ECW, van der Vorst MJDL, Boddaert MSA, Verdegaal BATT, Beeker A, Teunissen SCC, Beekman ATF, Zuurmond WWA, Berkhof J, Verheul HMW.

BMC Cancer. 2019 Feb 19;19(1):160. doi: 10.1186/s12885-019-5351-8.

14.

Prophylactic human papilloma virus vaccination in head and neck: indications and future perspectives.

Wierzbicka M, Berkhof JH, Dikkers FG.

Curr Opin Otolaryngol Head Neck Surg. 2019 Apr;27(2):85-90. doi: 10.1097/MOO.0000000000000525. Review.

PMID:
30694913
15.

Fast approximate computation of cervical cancer screening outcomes by a deterministic multiple-type HPV progression model.

Vänskä S, Bogaards JA, Auranen K, Lehtinen M, Berkhof J.

Math Biosci. 2019 Mar;309:92-106. doi: 10.1016/j.mbs.2019.01.006. Epub 2019 Jan 16.

PMID:
30659822
16.

Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.

Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, Meijer CJLM, Quint WGV, Snijders PJF, Massuger LFAG, van Kemenade FJ, Berkhof J.

Lancet Oncol. 2019 Feb;20(2):229-238. doi: 10.1016/S1470-2045(18)30763-0. Epub 2019 Jan 15.

PMID:
30658933
17.

HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme.

Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer CJLM.

Prev Med. 2019 Feb;119:108-117. doi: 10.1016/j.ypmed.2018.12.021. Epub 2018 Dec 27. Review.

18.

Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.

Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer CJLM, Berkhof J.

Int J Cancer. 2019 May 1;144(9):2339-2346. doi: 10.1002/ijc.32004. Epub 2019 Jan 10.

PMID:
30565673
19.

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia.

Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer's Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group, van der Flier WM.

Alzheimers Dement. 2019 Mar;15(3):465-476. doi: 10.1016/j.jalz.2018.10.003. Epub 2018 Dec 13.

20.

Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention.

Qendri V, Schurink-Van 't Klooster TM, Bogaards JA, Berkhof J.

Expert Rev Vaccines. 2018 Dec;17(12):1093-1104. doi: 10.1080/14760584.2018.1547196. Epub 2018 Nov 29. Review.

PMID:
30417704
21.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16.

22.

HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions.

Zummeren MV, Kremer WW, Leeman A, Bleeker MCG, Jenkins D, Sandt MV, Doorbar J, Heideman DAM, Steenbergen RDM, Snijders PJF, Kenter GG, Quint WGV, Berkhof J, Meijer CJLM.

Mod Pathol. 2018 Dec;31(12):1842-1850. doi: 10.1038/s41379-018-0101-z. Epub 2018 Aug 22.

PMID:
30135508
23.

Pricing of HPV vaccines in European tender-based settings.

Qendri V, Bogaards JA, Berkhof J.

Eur J Health Econ. 2019 Mar;20(2):271-280. doi: 10.1007/s10198-018-0996-9. Epub 2018 Jul 26.

24.

Three-tiered score for Ki-67 and p16ink4a improves accuracy and reproducibility of grading CIN lesions.

van Zummeren M, Leeman A, Kremer WW, Bleeker MCG, Jenkins D, van de Sandt M, Heideman DAM, Steenbergen R, Snijders PJF, Quint WGV, Berkhof J, Meijer CJLM.

J Clin Pathol. 2018 Nov;71(11):981-988. doi: 10.1136/jclinpath-2018-205271. Epub 2018 Jul 16.

25.

Human papillomavirus (HPV) prevalence and associated risk factors in women from Curaçao.

Hooi DJ, Lissenberg-Witte BI, Kenter G, de Koning MNC, Gomes Bravio I, Ardts K, Kleinmoedig S, Benita E, Pinedo HM, Berkhof J, Quint WGV, Meijer CJLM.

PLoS One. 2018 Jul 13;13(7):e0199624. doi: 10.1371/journal.pone.0199624. eCollection 2018.

26.

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.

Kaspers GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, Lopez-Yurda M, Berkhof J, Cloos J, de Haas V, Mathôt RA, Attarbaschi A, Baruchel A, de Bont ES, Fagioli F, Rössig C, Klingebiel T, De Moerloose B, Nelken B, Palumbo G, Reinhardt D, Rohrlich PS, Simon P, von Stackelberg A, Zwaan CM.

Br J Haematol. 2018 May;181(4):523-527. doi: 10.1111/bjh.15233. Epub 2018 Apr 20.

PMID:
29676440
27.

Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.

De Strooper LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, Snijders PJF, Meijer CJLM, Heideman DAM.

Int J Cancer. 2018 Sep 15;143(6):1541-1548. doi: 10.1002/ijc.31539. Epub 2018 Apr 27.

28.

Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples.

Verlaat W, Snoek BC, Heideman DAM, Wilting SM, Snijders PJF, Novianti PW, van Splunter AP, Peeters CFW, van Trommel NE, Massuger LFAG, Bekkers RLM, Melchers WJG, van Kemenade FJ, Berkhof J, van de Wiel MA, Meijer CJLM, Steenbergen RDM.

Clin Cancer Res. 2018 Jul 15;24(14):3456-3464. doi: 10.1158/1078-0432.CCR-17-3615. Epub 2018 Apr 9.

29.

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C.

Lancet Public Health. 2016 Nov;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9. Epub 2016 Sep 27. Review.

30.

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Dec 1;74(12):1481-1491. doi: 10.1001/jamaneurol.2017.2712.

31.

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.

Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer CJLM, Berkhof J.

Br J Cancer. 2017 Nov 7;117(10):1557-1561. doi: 10.1038/bjc.2017.309. Epub 2017 Sep 7.

32.

Identification of patients with cancer with a high risk to develop delirium.

Neefjes ECW, van der Vorst MJDL, Verdegaal BATT, Beekman ATF, Berkhof J, Verheul HMW.

Cancer Med. 2017 Aug;6(8):1861-1870. doi: 10.1002/cam4.1106. Epub 2017 Jul 7.

33.

Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.

Veldhuijzen NJ, Polman NJ, Snijders PJF, Meijer CJLM, Berkhof J.

Int J Cancer. 2017 Oct 15;141(8):1551-1560. doi: 10.1002/ijc.30865. Epub 2017 Jul 18.

34.

An EM algorithm for nonparametric estimation of the cumulative incidence function from repeated imperfect test results.

Witte BI, Berkhof J, Jonker MA.

Stat Med. 2017 Sep 20;36(21):3412-3421. doi: 10.1002/sim.7373. Epub 2017 Jun 20.

PMID:
28631295
35.

Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands.

Qendri V, Bogaards JA, Berkhof J.

J Infect Dis. 2017 Jul 15;216(2):210-219. doi: 10.1093/infdis/jix272.

PMID:
28586466
36.

Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing.

McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA.

Cancer Causes Control. 2017 Mar;28(3):203-214. doi: 10.1007/s10552-017-0870-6. Epub 2017 Feb 17.

PMID:
28213874
37.

Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.

Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, Farley C, Monsonego J, Franceschi S.

Int J Cancer. 2017 May 15;140(10):2192-2200. doi: 10.1002/ijc.30579. Epub 2017 Jan 11. Review.

38.

Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.

Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J.

BMJ. 2016 Oct 4;355:i4924. doi: 10.1136/bmj.i4924. Erratum in: BMJ. 2016 Oct 27;355:i5782.

39.

Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.

Polman NJ, Uijterwaal MH, Witte BI, Berkhof J, van Kemenade FJ, Spruijt JW, van Baal WM, Graziosi PG, van Dijken DK, Verheijen RH, Helmerhorst TJ, Steenbergen RD, Heideman DA, Ridder R, Snijders PJ, Meijer CJ.

Int J Cancer. 2017 Jan 15;140(2):423-430. doi: 10.1002/ijc.30449. Epub 2016 Oct 11.

40.

Resilience of a FIT screening programme against screening fatigue: a modelling study.

Greuter MJ, Berkhof J, Canfell K, Lew JB, Dekker E, Coupé VM.

BMC Public Health. 2016 Sep 22;16(1):1009.

41.

A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization.

Vink MA, Berkhof J, van de Kassteele J, van Boven M, Bogaards JA.

PLoS One. 2016 Aug 18;11(8):e0161109. doi: 10.1371/journal.pone.0161109. eCollection 2016.

42.

Management of high-risk HPV-positive women for detection of cervical (pre)cancer.

Luttmer R, De Strooper LM, Steenbergen RD, Berkhof J, Snijders PJ, Heideman DA, Meijer CJ.

Expert Rev Mol Diagn. 2016 Sep;16(9):961-74. doi: 10.1080/14737159.2016.1217157. Epub 2016 Aug 5. Review.

PMID:
27459506
43.

Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN.

Uijterwaal MH, van Zummeren M, Kocken M, Luttmer R, Berkhof J, Witte BI, van Baal WM, Graziosi GCM, Verheijen RHM, Helmerhorst TJM, van Dijken DKE, Spruijt JWM, van Kemenade FJ, Fransen-Daalmeijer N, Bekker-Lettink M, Heideman DAM, Snijders PJF, Steenbergen RDM, Meijer CJLM.

Gynecol Oncol. 2016 Oct;143(1):135-142. doi: 10.1016/j.ygyno.2016.07.089. Epub 2016 Jul 16.

PMID:
27430395
44.

FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.

Luttmer R, De Strooper LM, Dijkstra MG, Berkhof J, Snijders PJ, Steenbergen RD, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, van Baal WM, Graziosi PG, Quint WG, Spruijt JW, van Dijken DK, Heideman DA, Meijer CJ.

Br J Cancer. 2016 Aug 23;115(5):579-87. doi: 10.1038/bjc.2016.200. Epub 2016 Jul 14.

45.

Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma.

Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J.

Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1224-30. doi: 10.1158/1055-9965.EPI-16-0019. Epub 2016 Jun 2.

46.

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, Stoker J, Coupé VM.

Br J Radiol. 2016 Jul;89(1063):20150910. doi: 10.1259/bjr.20150910. Epub 2016 May 19.

47.

p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.

Luttmer R, Dijkstra MG, Snijders PJ, Berkhof J, van Kemenade FJ, Rozendaal L, Helmerhorst TJ, Verheijen RH, Ter Harmsel WA, van Baal WM, Graziosi PG, Quint WG, Spruijt JW, van Dijken DK, Heideman DA, Meijer CJ.

Mod Pathol. 2016 Aug;29(8):870-8. doi: 10.1038/modpathol.2016.80. Epub 2016 May 6.

48.

Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.

De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, Bosgraaf RP, Bekkers RLM, Massuger LFAG, Melchers WJG, Steenbergen RDM, Snijders PJF, Meijer CJLM, Heideman DAM.

Gynecol Oncol. 2016 May;141(2):341-347. doi: 10.1016/j.ygyno.2016.02.012. Epub 2016 Mar 3.

49.

Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.

Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, Verheul HM.

J Clin Oncol. 2016 Apr 20;34(12):1339-44. doi: 10.1200/JCO.2015.63.6043. Epub 2016 Feb 22.

PMID:
26903572
50.

Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.

Hesselink AT, Sahli R, Berkhof J, Snijders PJ, van der Salm ML, Agard D, Bleeker MC, Heideman DA.

J Clin Virol. 2016 Mar;76:36-9. doi: 10.1016/j.jcv.2016.01.009. Epub 2016 Jan 15.

Supplemental Content

Loading ...
Support Center